Computer Modelling and Visualization of Active Site of Monoamine Oxidases

NeuroToxicology

Volumn 25, Issue 1-2, 2004, Pages 37-46

  Veselovsky, Alexander V ^a   Ivanov, Alexey S ^a   Medvedev, Alexei E ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Computer modelling; Monoamine oxidase; Visualization

Indexed keywords

4 CHLORO N [2 (2 HYDROXYETHYLAMINO)ETHYL]BENZAMIDE; AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; CARBAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISATIN DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PARGYLINE; PHENELZINE; PIRLINDOLE; PYRAZINOCARBAZOLE; UNCLASSIFIED DRUG;

COMPUTER MODEL; CRYSTAL STRUCTURE; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME SUBSTRATE; GENETIC SCREENING; HUMAN; INCUBATION TIME; MITOCHONDRION; MOLECULAR MODEL; MOLECULAR SIZE; NONHUMAN; NUCLEOTIDE BINDING SITE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; THREE DIMENSIONAL IMAGING;

EID: 0347415717     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(03)00087-1     Document Type: Article

References (21)

1. Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 2002;9:22-6.
2. Cesura AM, Pletscher A. The new generation of monoamine oxidase inhibitors. Progr Drug Res 1992;38:171-297.
3. Gorkin VZ. Amine oxidases in clinical research. Oxford: Pergamon Press; 1983.
4. Harfenist M, Joyner CT, Mize PD, White HL. Selective inhibitors of monoamine oxidase, arylamide SAR. J Med Chem 1994;37:2085-9.
5. Ivanov AS, Medvedev AE, Lyulkin YA, Skvortsov VS, Rumjantsev AB, Gorkin VZ. Computer modelling of active site of monoamine oxidase A. In: Proceedings of the 14th European Workshop on Drug Metabolism, 1994 July 4-8; Paris, France. p. 66.
6. Krueger MJ, Efange SM, Michelson RH, Singer TP. Interaction of flexible analogues of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of N-methyl-4-phenylpyridinium with highly purified monoamine oxidase A and B. Biochemistry 1992;31:5611-5.
7. Krueger MJ, Mazouz F, Ramsay RR, Milcent R, Singer TP. Dramatic species differences in the susceptibility of monoamine oxidase B to a group of powerful inhibitors. Biochem Biophys Res Commun 1995;206:556-62.
8. Mabic S, Castagnoli Jr, N. Assessment of structural requirements for the monoamine oxidase-B-catalyzed oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridine derivatives related to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Med Chem 1996;39:3694-700.
9. Medvedev AE, Goodwin B, Clow A, Halket J, Glover V, Sandler M. Inhibitory potency of some isatin analogues on human monoamine oxidase A and B. Biochem Pharmacol 1992a;44:590-2.
10. Medvedev A, Gorkin V, Shvedov V, Fedotova O, Fedotova I, Semiokhina A. Efficacy of pirlindole, a highly selective reversible inhibitor of monoamine oxidase type A, in the prevention of experimentally induced epileptic seizures. Drug Invest 1992b;4:501-7.
11. Medvedev AE, Ivanov AS, Kamyshanskaya NS, Kirkel AZ, Moskvitina TA, Gorkin VZ et al. Interaction of indole derivatives with monoamine oxidase A and B. Studies on the structure-inhibitory activity relationship. Biochem Mol Biol Int 1995;36:113-22.
12. Medvedev AE, Ivanov AS, Veselovsky AV, Skvortsov VS, Archakov AI. QSAR analysis of indole analogues as monoamine oxidase inhibitors. J Chem Inform Comput Sci 1996;36:664-71.
13. Medvedev AE, Veselovsky AV, Shvedov VI, Tikhonova OV, Moskvitina TA, Fedotova OA et al. Inhibition of monoamine oxidase by pirlindole analogues: 3D-QSAR and CoMFA analysis. J Chem Inform Comput Sci 1998;38:1137-44.
14. Medvedev AE, Ramsay RR, Ivanov AS, Veselovsky AV, Shvedov VI, Tikhonova OV et al. Inhibition of monoamine oxidase by pirlindole analogues: 3D-QSAR analysis. Neurobiology 1999;7:151-8.
15. Medvedev AE, Ivanov AS, Veselovsky AV. One amino acid residue cannot determine the differences in the catalytic and regulatory properties of monoamine oxidases A and B. Biochem Moscow 2001;66:581-3.
16. Palmer SL, Mabic S, Castagnoli Jr, N. Probing the active sites of monoamine oxidase A and B with 1,4-disubstituted tetrahydropyridine substrates and inactivators. J Med Chem 1997;40:1982-9.
17. Panova NG, Zemskova MA, Axenova LN, Medvedev AE. Does isatin interact with rat brain monoamine oxidases in vivo? Neurosci Lett 1997;233:58-60.
18. Veselovsky AV, Medvedev AE, Tikhonova OV, Skvortsov VS, Ivanov AS. Modelling of substrate-binding region of the active site of monoamine oxidase A. Biochem Moscow 2000;65:910-6.
19. Veselovsky AV, Tikhonova OV, Ivanov AS, Medvedev AE. Monoamine oxidase B active site modelling by means of computer moulding. Vopr Med Khim 2001;47:642-51 [in Russian].
20. Wouters J. Structural aspects of monoamine oxidase and its reversible inhibition. Curr Med Chem 1998;5:137-62.
21. Wouters J, Moureau F, Vercauteren DP, Evrard G, Durant F, Koenig JJ et al. Experimental and theoretical study of reversible monoamine oxidase inhibitors: structural approach of the active site of the enzyme. J Neural Trans 1994;41(Suppl):313-9.